Glaukos Corporation (GKOS) Stock Price & How to Invest

Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. It pioneered Micro-Invasive Glaucoma Surgery (MIGS) with the iStent family of implants and has expanded into sustained-release drug delivery with iDose TR (a glaucoma implant) and corneal therapies including Photrexa and the newer Epioxa cross-linking treatment for keratoconus. The company sells through eye surgeons and clinics in the US and internationally, and reported record Q1 2026 net sales of roughly $150.6 million, up about 41% year over year, with its US glaucoma franchise up roughly 58% and iDose TR contributing around $54 million.

The investment picture is a classic growth-versus-profitability tradeoff. Revenue is compounding quickly and management raised full-year 2026 net-sales guidance to roughly $620 million to $635 million, yet Glaukos is still reporting net losses (about $19.8 million, or $0.34 per share, in Q1 2026) as it spends heavily on commercial launches and R&D. It carries roughly $280 million in cash and short-term investments with no debt, which funds those launches, but the stock trades at a rich multiple of sales and a negative P/E, so the valuation leans on continued rapid adoption of iDose TR and Epioxa. Walnut is not an investment adviser; this is descriptive context, not a recommendation.

Glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Reimbursement complexity is a recurring watchpoint, including Medicaid Drug Rebate Program impacts that have muted Photrexa and general pricing pressure in glaucoma devices. Competition is intense from Alcon, Sight Sciences, AbbVie, Johnson & Johnson, and others across MIGS and glaucoma drug delivery, and a competitor supply recovery or new launch could erode share. The legacy iStent business has shown flattish trends outside iDose, and international markets face new competitive product trialing. Heavy spending relative to current earnings means execution and continued access to capital both matter.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Glaukos Corporation's investor relations page or your broker.

• Revenue (TTM): ~$470M
• Q1 2026 net sales: ~$150.6M (up ~41% YoY)
• 2026 revenue guidance: ~$620M to $635M
• Q1 2026 net loss: ~$19.8M (~$0.34/share)
• Market cap: ~$6B
• Cash and short-term investments: ~$280M (no debt)

Glaukos combines roughly 40% revenue growth with ongoing net losses, so it screens as a high-multiple growth medtech rather than a value name (negative trailing P/E). The debt-free balance sheet and roughly $280 million in cash fund the iDose TR and Epioxa launches. Wall Street price targets in 2026 ranged widely, from about $72 to $165, reflecting disagreement over how quickly the newer products scale.

There are three common ways to get GKOS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so GKOS sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where GKOS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

GKOS is a fast-growing, cash-funded eye-care medtech whose story rides on new-product adoption outpacing competition and reimbursement risk while it works toward profitability.

Whether GKOS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GKOS a buy?, and where the stock could go from here in the GKOS stock forecast.

For income investors, whether GKOS pays a dividend and how the payout looks is covered in does GKOS pay a dividend?